Btk Inhibitor Compounds Modulating B-cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis and asthma, often have limitations in effectively targeting Bruton's Tyrosine Kinase (Btk) activity, which is crucial for B-cell activation and proliferation, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of novel Btk inhibitor compounds, specifically represented by Formula I, which are administered to patients to inhibit Btk activity, thereby modulating B-cell development and reducing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for autoimmune and inflammatory diseases, then they provide some therapeutic effect, but they fail to effectively target Btk activity leading to suboptimal outcomes
Solution Approach 1:
The patent employs parameter changes by developing novel chemical compounds with specific molecular structures (Formula I) that are optimized to bind to and inhibit Btk. The compounds feature specific substituent patterns (R1-R6 groups) that can be varied to optimize binding affinity and selectivity for Btk, thereby improving therapeutic effectiveness while maintaining ease of manufacture through systematic structure-activity relationship optimization
2Reliability
If Btk inhibitor compounds are developed to effectively inhibit Btk activity, then therapeutic benefits are improved, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies this principle by developing small molecular weight compounds that can be administered orally or by injection, replacing complex biologic therapies. These small molecule inhibitors are designed to be stable, manufacturable, and deliverable through simple routes, reducing treatment complexity while maintaining therapeutic benefits
3Reliability
If selective Btk inhibitors are used to block B-cell mediated disease processes, then disease progression is ameliorated, but off-target effects on other kinases may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target the unique ATP-binding pocket of Btk. The molecular structure includes specific substituents (R1-R6) that are positioned to interact with residues unique to Btk, providing selective inhibition while minimizing off-target effects on other kinases
Data Source
AI summary
This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.